WO2006136871A1 - Utilisation d'extraits de pollen pour traiter des infections, des neoplasmes et pour equilibrer la reponse immunitaire - Google Patents
Utilisation d'extraits de pollen pour traiter des infections, des neoplasmes et pour equilibrer la reponse immunitaire Download PDFInfo
- Publication number
- WO2006136871A1 WO2006136871A1 PCT/IB2005/001750 IB2005001750W WO2006136871A1 WO 2006136871 A1 WO2006136871 A1 WO 2006136871A1 IB 2005001750 W IB2005001750 W IB 2005001750W WO 2006136871 A1 WO2006136871 A1 WO 2006136871A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- immune response
- pollen
- neoplasms
- balance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
Definitions
- This invention relates to the use of pollen extracts to prepare medicinal products designed to activate/rebalance the immune response.
- Pollen has a complex chemical composition and comprises proteins and aminoacids, carbohydrates, lipids, mineral salts and trace elements, vitamins, hormones, enzymes, growth factors, water-extractable antibiotic substances and nucleic acids.
- Pollen extracts which are available on the market from a number of sources, are mainly used in the cosmetic field, as active ingredients of formulations for dry, normal and greasy skins due to their nutrient properties.
- Pollen extracts obtained by extraction of pollens of various origins with aqueous, hydroalcoholic, oily or glycolic solvents, are also used as tonics and as adjuvants in the treatment of states of mental and physical fatigue, depression and asthenia.
- EP 1077725 filed by the Applicant, discloses that the association of pollen extract with vegetable oil unsaponifiables, applied topically, is suitable to treat a number of conditions, mainly of dermatological and circulatory interest, with an inflammatory, immune, degenerative or proliferative base.
- EP 1313492-6 disclose the use of pollen extracts, possibly associated with royal jelly and Vitamin E, to treat dysphoria associated with normal hormonal variations in women of childbearing, peri- and post-menopausal age.
- Chinese patents CN1391911 and WO99/11279 disclose the use of pollen extracts for the treatment of benign prostatic hyperplasia and prostatitis.
- pollen extracts suitably formulated for oral, topical, transdermal, intramuscular or intravenous administration, has led to improvements in infectious diseases and neoplastic disorders, and often to a cure.
- the pollen extracts which can be used according to the invention may be of different types and origins, such as hydroalcoholic, aqueous, oily or glycol extracts.
- the extracts will be administered by oral, parenteral or topical administration, depending on the site affected by the disorder to be treated, at doses which can vary within a wide range in view of the substantial absence of toxicity of the extract. Broadly speaking, 10 mg to 500 mg a day can be given in one or more administrations by the oral or parenteral route, while a formulation of 0.1 to 10% in weight of extract can be used for topical or transdermal administration.
- the extracts will be suitably formulated in transdermal systems, capsules, tablets, solutions for oral or parenteral use, suspensions, creams, gels or the like, in association with conventional excipients or vehicles, and possibly with other active ingredients with a complementary or otherwise useful activity.
- the transdermal formulations may contain suitable absorption promoters in conventional use.
- disorders that respond to the treatment according to the invention include:
- Oncological disorders such as tumours in situ, affecting the limbs and lymph node stations or at an advanced stage.
- non-Hodgkin's lymphoma even at an advanced stage of the disease, such as the 3rd or 4th stage according to the TNM classification
- the treatment of these disorders requires from 4-5 days to several months' application of the gel or transdermal system to which the invention relates.
- the treatment may also be accompanied by the administration of pollen extract, especially oral administration.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
L'invention a pour objet l'utilisation d'extrait de pollen pour préparer des produits médicinaux pour le traitement d'infections systémiques et de troubles néoplasiques qui peuvent être localisés ou à un stade avancé.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2005/001750 WO2006136871A1 (fr) | 2005-06-21 | 2005-06-21 | Utilisation d'extraits de pollen pour traiter des infections, des neoplasmes et pour equilibrer la reponse immunitaire |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2005/001750 WO2006136871A1 (fr) | 2005-06-21 | 2005-06-21 | Utilisation d'extraits de pollen pour traiter des infections, des neoplasmes et pour equilibrer la reponse immunitaire |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006136871A1 true WO2006136871A1 (fr) | 2006-12-28 |
Family
ID=36084216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2005/001750 WO2006136871A1 (fr) | 2005-06-21 | 2005-06-21 | Utilisation d'extraits de pollen pour traiter des infections, des neoplasmes et pour equilibrer la reponse immunitaire |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006136871A1 (fr) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4952399A (en) * | 1985-09-20 | 1990-08-28 | Cernitin Sa | Pharmaceutical composition which inhibits the growth of a tumor |
RU2090198C1 (ru) * | 1991-03-12 | 1997-09-20 | Иван Иванович Уваров | Способ получения биологически активных веществ, обладающих противогрибковой активностью |
US5712377A (en) * | 1995-06-30 | 1998-01-27 | Cerbios-Pharma Sa | Glycosides isolated from pollen, their sugar-free decomposition products and derivatives thereof |
WO2002032442A1 (fr) * | 2000-10-20 | 2002-04-25 | Biolee Co., Ltd. | Preparation externe pour la peau contenant du pollen de pin ou un extrait de celui-ci |
EP1364943A1 (fr) * | 2001-02-02 | 2003-11-26 | Ajinomoto Co., Inc. | Nouveaux derives de cystine et inhibiteurs de l'activation des facteurs inflammatoires |
US20040147459A1 (en) * | 2002-10-23 | 2004-07-29 | Joseph Oneal | Method and composition for maintaining urinary tract health in the face of infections |
-
2005
- 2005-06-21 WO PCT/IB2005/001750 patent/WO2006136871A1/fr active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4952399A (en) * | 1985-09-20 | 1990-08-28 | Cernitin Sa | Pharmaceutical composition which inhibits the growth of a tumor |
RU2090198C1 (ru) * | 1991-03-12 | 1997-09-20 | Иван Иванович Уваров | Способ получения биологически активных веществ, обладающих противогрибковой активностью |
US5712377A (en) * | 1995-06-30 | 1998-01-27 | Cerbios-Pharma Sa | Glycosides isolated from pollen, their sugar-free decomposition products and derivatives thereof |
WO2002032442A1 (fr) * | 2000-10-20 | 2002-04-25 | Biolee Co., Ltd. | Preparation externe pour la peau contenant du pollen de pin ou un extrait de celui-ci |
EP1364943A1 (fr) * | 2001-02-02 | 2003-11-26 | Ajinomoto Co., Inc. | Nouveaux derives de cystine et inhibiteurs de l'activation des facteurs inflammatoires |
US20040147459A1 (en) * | 2002-10-23 | 2004-07-29 | Joseph Oneal | Method and composition for maintaining urinary tract health in the face of infections |
Non-Patent Citations (2)
Title |
---|
DATABASE WPI Section Ch Week 199823, Derwent World Patents Index; Class B04, AN 1998-259253, XP002375085 * |
WÓJCICKI J ET AL: "The effect of Cernitins on galactosamine-induced hepatic injury in rat.", ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS. 1985, vol. 33, no. 2, 1985, pages 361 - 370, XP008062497, ISSN: 0004-069X * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8158161B2 (en) | Methods and pharmaceutical compositions useful for treating psoriasis | |
WO2002013835A1 (fr) | Composition presentant un effet antioxydant synergique | |
CN1264526C (zh) | 贯叶金丝桃的改进和稳定提取物及其制备方法和作为局部药物的用途 | |
EP2953628B1 (fr) | Creme a base de basidiomycetes pour le traitement des maladies cutanees | |
US20080070875A1 (en) | Acne treatment compositions and methods of use | |
JP2004507496A5 (fr) | ||
WO2019223699A1 (fr) | Polysaccharide biologique pour la prévention et le traitement de l'acné et de la dermatite liée aux stéroïdes et son utilisation | |
JPH11501284A (ja) | アポトーシスを阻害する組成物、その組成物の精製方法およびその使用 | |
WO2018023126A1 (fr) | Procédés de traitement de l'osmidrose | |
HUP0402318A2 (hu) | Ciklosporint tartalmazó gyógyászati készítmény és alkalmazása | |
CN108295095A (zh) | 红色诺卡氏菌细胞壁骨架在制备治疗痤疮的药物/护肤品中的用途及其药物/护肤品组合物 | |
WO2006136871A1 (fr) | Utilisation d'extraits de pollen pour traiter des infections, des neoplasmes et pour equilibrer la reponse immunitaire | |
US20140107223A1 (en) | Topical ubiquinol supplement skin care compositions | |
TW200816984A (en) | Naphthalenedione compounds | |
US10376488B2 (en) | Use of flavonoids in manufacturing compositions for wound healing | |
JP3072321B2 (ja) | 抗hiv活性物質およびその製造方法 | |
Dreno | Roferon‐A (interferon alpha 2a) combined with tigason (etretinate) for treatment of cutaneous T cell lymphomas | |
JP3246683B2 (ja) | 細胞増殖促進物質及びそれを含有する組成物 | |
RU2535053C2 (ru) | Фармацевтическая композиция, содержащая лизин и ферменты: лизоцим, дезоксирибонуклеазу и/или пероксидазу для наружного лечения и профилактики инфекций, вызванных вирусом герпеса типа 1,2 и бактериальных осложнений, вызываемых герпетической инфекцией | |
WO2003037380A1 (fr) | Chlorambucil parenteral utilise dans le traitement de maladies malignes et auto-immunes, et procedes d'utilisation associes | |
JPH10298099A (ja) | 細胞賦活組成物 | |
US20120082742A1 (en) | Method and compositions for treating cutaneous verrucae | |
JPH0827015A (ja) | ブドウ色素を含有する飼料 | |
Rakhmanovna et al. | Influence of haplogenin-7-glycoside on respiration and oxidative phosphorylation of rat liver mitochondria | |
RU2519133C1 (ru) | Мазь, содержащая инкапсулированную тритерпеновую кислоту или ее производные |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05772299 Country of ref document: EP Kind code of ref document: A1 |